Savara Inc.（SVRA）股價、財務與研究

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

45/ 100

GoAI評分

Hold

Wait — insufficient conviction to act

估值

32

Expensive

動能

65

Gaining

情緒

50

Mixed

風險韌性

68

Moderate Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Matthew Pauls
上市以來: 2017年4月28日
僱員: 70

市場位置

日內區間

目前US$5.49，

US$5.42US$5.625

52週區間

目前US$5.49，

US$3.08US$7.005

開盤價: US$5.60
前收盤價: US$5.59
成交量: 35.03萬; 0.21× 平均值
平均成交量: 164.41萬; 日均成交量
市值: 11.25億 USD
貝塔: 0.26; 市場參考 1
50天平均值: US$5.6666; 低於平均水平-3.12%
200天平均值: US$5.518; 低於平均水平-0.51%

財務數據

財務快照

估值與收益率

企業價值: 13.38億 USD
本益比（TTM）: -9.47×
股價淨值比（TTM）: 9.69×
股價營收比（TTM）: 0×
EV/EBITDA: -11.28×
盈餘收益率: -8.86%
自由現金流收益率: -7.54%
股息率: 0.00%

獲利能力和效率

毛利率: 0.00%
營業利益率: 0.00%
淨利潤率: 0.00%
股東權益報酬率: -58.50%
資產報酬率: -46.89%
投入資本報酬率: -53.01%

財務健康

負債權益比: 0.21×
流動比率: 11.85×

財報歷史與展望

EPS優於預期率: 9%; 優於預期1次、低於預期8次、符合預期2次
平均EPS意外幅度: -6.56%; 11 類似報告
最新每股收益結果: -0.16; 預估-0.14 · 低於預期13.27%

EPS：實際值與預估值

近期已公布業績

實際值預估值

營收：實際值與預估值

近期已公布業績

實際值預估值

分析師評級

第三方分析師預期可能變動，並非 GoAI 建議。

分析師目標價

平均目標

US$10.00

上漲空間 82.15%

過去 12 個月12個月預測最高：US$10.00平均的：US$10.00最低：US$10.00

SVRA 訊息

businesswire.com2026年8月20日

Savara Announces New Employment Inducement Grant

YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On August 17,…

閱讀原始碼

businesswire.com2026年8月11日

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June…

閱讀原始碼

seekingalpha.com2026年8月5日

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

Savara Inc. (SVRA) is revisited, focusing on its APAP BLA filing progress. The article assesses SVRA's clinical and regulatory milestones as key investment drivers. Upcoming APAP BLA PDUFA is highlighted as a pivotal…

閱讀原始碼

businesswire.com2026年7月30日

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO) has…

閱讀原始碼

zacks.com2026年7月22日

Here's Why You Should Add Savara Stock to Your Portfolio Now

SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.

閱讀原始碼

fool.com2026年6月27日

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

394,528 shares of Common Stock were sold for about $2.24 million on June 22, 2026, at a weighted average price of around $5.68 per share. This transaction represented 42.40% of the executive's total common stock holdings…

閱讀原始碼